AR and prostate cancer: Androgen receptor (AR) splice variants (AR-Vs) have been described as a potential mechanism of resistance to AR targeted agents (ARTA), e.g. enzalutamide or abiraterone in prostate cancer (PC), eventually leading to castration resistant prostate cancer (CRPC) [1, 2].